A Agilent Technologies
A quality recurring-revenue tools franchise in recovery, but at about 2x my value the price assumes perfection.
The story
Agilent is a mature life-science and diagnostics tools franchise. About two-thirds of revenue is recurring (consumables, service contracts, software), and that base sits on a large installed base of LC/MS and genomics instruments. After a 2023-24 destocking and China-driven trough, revenue is recovering: TTM is $7.37B, up about 6% on FY24. The moat is customer lock-in through validated workflows and service attach. Growth is still mid-single-digit, held back by pharma and academic capex cycles and tariff/China exposure.
The facts confirm the recovery story, so I kept every driver except a small move in year-1 growth from 6% to 6.5% (under 20% relative), reflecting TTM revenue up about 6% with order momentum improving. The margin target stays at 26%: the current 23.9% is below the 2019-21 run-rate, and the Ignite cost program supports a return to the mid-20s, not the peak. Sales-to-capital stays at an incremental 1.5 because the reported 0.73 is inflated by acquisition goodwill and overstates what organic growth costs to fund.
Value drivers
| Revenue growth (Y1) | 6.5% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 26.0% |
| Years to target margin | 5 |
| Sales-to-capital | 1.50 |
| Beta | 1.00 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 9.2% |
| Terminal WACC | 9.2% |
Valuation bridge
| PV of explicit FCFF | 12.26B |
| PV of terminal value | 16.56B |
| Equity value | 26.98B |
| ÷ shares → per share | $95.70 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 7.85B | 6.5% | 24.3% | 1.74B | 319.45M | 1.42B | 1.30B |
| 2 | 8.34B | 6.2% | 24.8% | 1.87B | 322.77M | 1.55B | 1.30B |
| 3 | 8.82B | 5.8% | 25.2% | 2.02B | 324.15M | 1.69B | 1.30B |
| 4 | 9.31B | 5.5% | 25.6% | 2.16B | 323.46M | 1.84B | 1.29B |
| 5 | 9.79B | 5.2% | 26.0% | 2.31B | 320.57M | 1.99B | 1.28B |
| 6 | 10.26B | 4.8% | 26.0% | 2.42B | 315.38M | 2.11B | 1.24B |
| 7 | 10.72B | 4.5% | 26.0% | 2.53B | 307.82M | 2.22B | 1.20B |
| 8 | 11.17B | 4.2% | 26.0% | 2.64B | 297.84M | 2.34B | 1.16B |
| 9 | 11.60B | 3.8% | 26.0% | 2.74B | 285.43M | 2.45B | 1.11B |
| 10 | 12.00B | 3.5% | 26.0% | 2.83B | 270.60M | 2.56B | 1.07B |
Key risks
- Pharma and biotech capex stays soft, or the NIH and academic funding cuts deepen
- China demand weakness and tariff-driven cost pressure compress margins
- Acquisitive reinvestment (e.g., BioVectra-style deals) earns returns below the cost of capital
Catalysts
- A sustained instrument replacement cycle in LC/LC-MS that lifts growth back above 7%
- Delivery of the Ignite margin program toward a 26%+ operating margin